Sentences with phrase «anti-cd47-mediated tumor rejection»

Dr. Sharma is a trained medical oncologist and immunologist whose research work is focused on investigating mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit.

This did induce an immune response but only led to tumor rejection in one - quarter of the animals.»

«Although both anti-CTLA-4 and anti-PD-1 improved tumor rejection, mice treated with anti-CTLA-4 exhibited superior tumor control, suggesting the memory T - cell response by this agent is more durable,» said Allison.

Pramod Srivastava and Lloyd J. Old identify the human homologue of the mouse tumor rejection antigen gp96.

Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin - 2 receptor alpha) monoclonal antibody.

Pramod Srivastava and M.R. Das identify the gp100 molecule as an individually specific tumor rejection antigen of a rat hepatoma.

The decreased tumor size and enhanced tumor rejection in DGKζ - deficient mice indirectly suggests that enhanced Erk signaling may be superior to enhanced NF - κΒ activation in facilitating T cell activity against tumor, especially because DKO mice did not exhibit improved tumor control relative to DGKζ − / − mice.

This molecule, belonging to the gp96 family, is the first heat shock protein identified as a tumor rejection antigen.

We observed enhanced tumor rejection in DGKζ - deficient mice and DKO mice relative to WT or Cbl - b — deficient mice.

IDO1 has been implicated in immune modulation through its ability to limit T cell function and engage mechanisms of immune tolerance, and as such preventing tumor rejection.

«Tumor rejection requires both innate and adaptive immune responses against tumor cells.

Not exact matches

Key studies in mice showed that NF - κB can mediate immune rejection of tumors.

The rejection of the tumor then worked in 80 percent of the test animals.

These tumor - rejection antigens may provide a basis for precisely targeted anticancer therapy

Aside from tumor recurrence, he could also be dealing with organ rejection or a possible hormone imbalance if the tumor is active.

Ectopic expression of retinoic acid early inducible - 1 gene (RAE - 1) permits natural killer cell - mediated rejection of a MHC class I - bearing tumor in vivo.

In their study, DN T cells displayed allospecific cytotoxicity in vitro and mediated tumor allograft rejection in vivo.

James P. Allison and Matthew Krummel demonstrate that a monoclonal antibody directed against the CTLA - 4 molecule in a mouse model of melanoma could result in the rejection of tumors and that this rejection also resulted in immunity to a second exposure to tumor cells.

Thus, in a single experiment, the authors demonstrated that (1) CD4 + and CD8 + T - cells were the mediators of immune system rejection of transplanted tumor cells, and (2) d42m1 escape tumors develop from T - cell - dependent selection favoring cells without the spectrin - B2 antigen.

Moreover, knock in animal models for syngeneic studies and allowing us to isolate transgenic armed effector cells are developed in order to show proof of concept for the diverse applicability of our modular targeting systems including for tumor diseases, autoimmune diseases, GvHD, transplantation / rejection as well as viral infections.

This single - celled algae also increases the activity of Natural Killer (NK) cells, a type of white blood cell that plays a major role in host rejection of tumors.

The reasons for rejection are many, but can include pest infestation, disease, cancerous tumors, mould, infection and a host of other highly unsavory conditions.

The odor associated with necrotic oral tumors can be offensive and cause social rejection by family members.